Neurovascular care remains one of the more complex and uncertain areas of modern medicine. Millions of people live with conditions such as intracranial aneurysms without symptoms, yet when an event occurs, the consequences are often catastrophic, carrying high mortality rates and a substantial risk of long-term neurological disability.
For neurospecialists, one of the most critical challenges is determining which cases can be safely monitored and which require intervention before a life-threatening event occurs.
That clinical uncertainty is the problem CARA Systems Inc. is attempting to address. The Brooklyn-based NYU spinout, led by Co-Founder and CEO Prithvinath Garigapuram, has developed a non-invasive clinical decision-support platform that integrates AI-driven medical imaging and patient-specific analytics into a unified workflow for neurovascular assessment. The company’s broader objective is to improve how complex neurovascular cases are evaluated by consolidating fragmented clinical and imaging information into a more consistent, interpretable, and patient-specific decision-making framework.
The Anatomy of a Difficult Call
Neurovascular decision-making and risk assessment relies on imaging interpretation, and patient-specific physiology. Current risk stratification methods still rely heavily on clinical frameworks centered around factors such as size, anatomical location, and basic patient demographics, but offer limited insight into the individualized anatomical and hemodynamic characteristics that may influence disease progression in a specific patient.
